Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prifetrastat - Pfizer

Next Previous
Drug Profile

Prifetrastat - Pfizer

Alternative Names: PF-07248144

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anisoles; Antineoplastics; Benzene derivatives; Isoxazoles; Methyl ethers; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Histone acetyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 16 Jan 2026 Pfizer completes a phase I trial for Solid tumours (In volunteers) in USA (PO, IV) (NCT07423286)
  • 14 Jan 2026 Pfizer in collaboration with UNICANCER plans a phase II UNLOCK-EPIBREAST trial HER2-negative breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in May 2026 (NCT07340619)
  • 13 Jan 2026 Pfizer plans a phase I pharmacokinetics trial in Healthy volunteers in USA (PO, Tablet) (NCT07335419) (C4551006)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top